Simplify Logo

Full-Time

Director of Business Development

Posted on 6/27/2024

TandemAI

TandemAI

51-200 employees

AI-driven platform for pre-clinical drug discovery

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology
Healthcare

Senior, Expert

New York, NY, USA

Category
Business Development
Business & Strategy
Required Skills
Sales
Business Analytics
Requirements
  • Bachelor’s degree required
  • 8+ years of experience in business development
  • Scientific and business education/experience preferred
  • Knowledge of biopharma and biotech industry trends
  • Ability to perform complex analyses
  • Fluency in business analytics and valuation methodologies
Responsibilities
  • Identify, evaluate, and transact new opportunities
  • Engage new clients through networking
  • Support current clients through business interactions
  • Negotiate business interactions with clients
  • Provide updates and sales projections to leadership

TandemAI provides an integrated platform for pre-clinical drug discovery, utilizing advanced computational tools, artificial intelligence, and supercomputing to simulate drug interactions with proteins at the molecular level. Their main product, TandemViz, offers web-based access to tools that visualize these interactions through dynamic physics-based simulations. This allows researchers to gain insights into drug efficacy and safety by processing large datasets and creating predictive models. Unlike competitors, TandemAI operates on a "Discovery as a Service" model, making their tools accessible to a wider range of researchers through subscription fees and service contracts. The company's goal is to accelerate the drug discovery process and improve the success rate of new treatments by fostering collaboration among scientists from various disciplines.

Company Stage

Series A

Total Funding

$60M

Headquarters

New York City, New York

Founded

2021

Growth & Insights
Headcount

6 month growth

3%

1 year growth

9%

2 year growth

93%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $35 million Series A financing will enable TandemAI to expand its computational and wet lab solutions, potentially accelerating drug discovery timelines.
  • The appointment of Alessandro Monge as Chief Business Officer brings valuable industry experience and could drive significant growth and strategic partnerships.
  • TandemAI's TandemViz 1.0 platform enhances user experience and collaboration, making advanced computational tools more accessible to a broader range of researchers.

What critics are saying

  • The competitive landscape in AI-driven drug discovery is intense, requiring continuous innovation to maintain a competitive edge.
  • Rapid expansion and scaling could lead to operational challenges and strain on resources, potentially impacting service quality.

What makes TandemAI unique

  • TandemAI's 'Discovery as a Service' model democratizes access to advanced drug discovery tools, unlike traditional models that require significant upfront investment.
  • The integration of AI with dynamic physics-based molecular simulations in TandemViz offers a unique, predictive approach to drug-protein interaction analysis.
  • TandemAI's multidisciplinary team and collaborative culture accelerate the drug discovery process, setting it apart from competitors with more siloed approaches.
INACTIVE